Photo courtesy SPCA of Brevard The U.S. Department of Agriculture has approved an expanded use for Elanco’s Canine Parvovirus Monoclonal Antibody (CPMA), allowing it to be administered as a preventive measure in puppies exposed to the virus. Previously used only to treat active infections, CPMA is now the first and only conditionally approved product in the U.S. for passive immunity against canine parvovirus. This development is expected to aid veterinarians and shelters in curbing outbreaks, particularly in high-risk areas. Photo courtesy SPCA of Brevard To increase access, Elanco has reportedly distributed more than $3 million worth of CPMA to 2,300 clinics and shelters nationwide. Early results suggest the expanded use could save thousands of puppies. In one Florida case, a shelter treated 27 parvovirus-positive puppies, marking the largest group saved with the treatment to date. States, such as Florida, Texas, Arizona, Georgia, Illinois, Indiana, and New York, have reported the highest recent rates of parvovirus outbreaks, according to ParvoTrack, a national monitoring tool introduced by Elanco in 2023. For more information, visit DefeatParvo.com.
